Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metyrapone versus placebo crossover study in mild autonomous cortisol secretion
2026-526837-24-00Phase 4Authorised
- Sponsor
- Medical University of Vienna
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of metyrapone in Mild hypercortisolism (SCS) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Hepatic lipid content. Planned start Oct 2026; status: authorised.
02
Drugs
metyrapone
03
Conditions
Mild hypercortisolism (SCS)
Beyond the preview
Go deeper on 2026-526837-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526837-24-00.